Navigation Links
Public Citizen Petitions FDA to Ban Diabetes Drug Avandia, According to Avandia Plaintiffs Attorney Group
Date:11/6/2008

National non-profit organization documents upsurge in negative clinical data associated with use of Avandia, urges FDA commissioner to remove drug from U.S. market immediately

Mineola, N.Y. (Lexis Nexis) November 6, 2008 -- Public Citizen, a non-profit organization representing more than 80,000 consumers nationwide, has petitioned the Commissioner of the U.S. Food and Drug Administration to immediately ban the diabetes drug Avandia, according to Marc Grossman, a member of the Avandia Plaintiffs Steering Committee.

According to the petition, recent clinical studies documented that Avandia has caused an increased risk of heart attacks, heart failure, bone fractures, anemia and retinal edema with vision loss. Perhaps most seriously, the group analyzed 14 cases of liver failure in patients who were taking Avandia, 12 of which resulted in death.

"In the past year, there were 4.6 million (Avandia) prescriptions filled, thus exposing hundreds of thousands of people with diabetes to a drug that is clearly doing more harm than good," according to the Public Citizen petition. "Thus, it is urgent for the FDA to immediately ban rosiglitazone (Avandia)."

The Avandia Plaintiffs Steering Committee has been tracking the reports of multiple serious side effects from Avandia for the past year and represents a number of plaintiffs in litigation against the manufacturer of the drug, GlaxoSmithKline. Many nationwide lawsuits have been centralized in Federal court in the Eastern District of Pennsylvania in front of Hon. Cynthia Rufe, (In Re: Avandia Marketing, Sales Practices and Products Liability Litigation, 2:07-md-01871-CMR). This litigation involves thousands of claims for injuries ranging from death and heart attack to vision loss and bone fractures.

"The Public Citizen petition, along with prior recommendations against the use of Avandia from both the American Diabetes Association and the European Association for the Study of Diabetes, is certainly a step in the right direction," said Vance Andrus, lead counsel for the Avandia Plaintiffs Steering Committee. "Many doctors and patients were led to believe that this was a safe and effective drug and, as a result, their lives were put in danger."

Any adverse reactions experienced with the use of Avandia should be reported to the FDA's MedWatch Program by phone at 1-800-FDA-1088, by mail at MedWatch, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at www.fda.gov/medwatch.

###

Read the full story at http://www.prweb.com/releases/2008/11/prweb1572304.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. International Medical Corps Continues Delivering Emergency Relief in Democratic Republic of Congo as Potential for Renewed Fighting Threatens to Deepen Crisis
2. Media Affects Public Perception of Infectious Diseases
3. International Medical Corps Continues Delivering Emergency Relief Amid Violence in Democratic Republic of Congo
4. Evolution Physical Therapy First Clinic in Southern California to Introduce NASA-Designed Anti-Gravity Treadmill for Public Use
5. NQF Endorses Guidelines for Consumer-Focused Public Reporting
6. Teach For America and Lilly Launch Program to Match Lilly Employees with Teachers in Underserved Public Schools
7. ASPH and APHA Collaborate to Shore up the Public Health Workforce Pipeline:
8. Home Health Leaders Launch Alliance to Sponsor Research and to Educate Public and Policymakers on Sectors Contributions to National Health Reform
9. Gather and Harvard Health Publications Launch New Programs to Bring Harvard Medical School Doctors Expertise Online
10. Bloomberg School of Public Health to lead nationwide aging study
11. New State Public Health Department Survey Results Highlight Available Resources for Men and Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... Donna Parker, L. Ac. reads ... not found any of them to be very practical. She wanted to write a ... make changes in their health. It prompted her in writing “ A Clear Path ...
(Date:4/24/2017)... ... April 24, 2017 , ... “The Saint with Trin, ... Trin, and Omega Station” is the creation of published author, Chris Jackson. Chris ... where he works in the Dallas Independent School District teaching English. He is heavily ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... development of next generation neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke ... its ANCD BRAIN device as the product advances towards regulatory and clinical phases. ...
(Date:4/22/2017)... , ... April 22, 2017 , ... Ecommerce sales have ... States estimated to be $394.9 billion. The consequences of rapid innovation and growth ... the limits of technology, it is every business and individual’s job to give something ...
(Date:4/22/2017)... ... 2017 , ... The San Juan Capistrano summer camp team at the Boys and ... for summer camps to provide physical activities for all campers. To read the report, ... , With an increase in specialty camps that focus on what the report terms as ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
(Date:4/19/2017)... 2017  Novartis today announced the publication of ... and Blood Institute (NHLBI) of the National Institutes ... with treatment-naïve severe aplastic anemia (SAA) achieved complete ... at the initiation of and concurrently with standard ... sequential treatment groups, or cohorts. Cohort 3 added ...
(Date:4/18/2017)... 2017 Cogentix Medical, Inc. (NASDAQ: CGNT), a ... Uro/Gyn and Gynecology markets with innovative and proprietary products, ... March 31, 2017 after the market close on Tuesday, ... host a conference call and webcast to discuss its ... 2017 at 4:30 p.m. Eastern Time (3:30 p.m. Central ...
Breaking Medicine Technology: